2seventy bio, Inc. - Common Stock TSVT 深 滬
等待開盤 09-20 09:30:00 美东时间
4.87
+0.150
+3.18%
華盛通- 最 高4.905
- 今 開4.89
- 成交量 17.25万股
- 最 低 4.77
- 昨 收 4.72
- 總市值 2.46亿
- 52周最高 6.40
- 市盈率 靜 --
- 換手率 0.34%
- 52周最低 1.535
- 委 比 -24.67%
- 總股本 5046.46万
- 歷史最高 44.34
- 量 比 0.56
- 振 幅 2.86%
- 歷史最低 1.535
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Analysts’ Opinions Are Mixed on These Healthcare Stocks: Walgreens Boots Alliance (WBA), 2seventy bio (TSVT) and Repare Therapeutics (RPTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings ...
08-29 21:37
2seventy Bio shares are trading higher after the company reported better-than-expected Q2 adjusted EPS results.
2seventy Bio shares are trading higher after the company reported better-than-e...
08-08 01:51
2seventy bio Q2 2024 Adj. EPS $(0.29) Beats $(0.65) Estimate, Sales $8.967M Miss $14.195M Estimate
2seventy bio (NASDAQ:TSVT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.65) by 55.38 percent. The company reported quarterly sales of $8.967 million which missed the
08-07 19:45
J&J says Carvykti beat standard drugs in late-stage blood cancer trial
Johnson & Johnson (NYSE:JNJ) announced Tuesday that its FDA-approved cell therapy Carvykti, developed with Legend Biotech (LEGN), outperformed standard of care in a Phase 3 trial for patients with a t...
07-02 20:23
2seventy bio(TSVT.US)盘前涨近4%！旗下A型血友病项目获诺和诺德(NVO.US)收购
2seventy bio宣布完成一项资产购买协议。根据该协议，诺和诺德将收购2seventy bio的A型血友病项目。此外，诺和诺德还将收购2seventy bio体内基因编辑技术的权利。
06-27 20:21
美股异动｜2seventy Bio盘后涨近7% 向诺和诺德出售血友病疗法
格隆汇6月27日｜2seventy Bio(TSVT.US)盘后涨近7%，报3.85美元。消息面上，2seventy Bio宣布，诺和诺德以4000万美元收购了...
06-27 10:05
2seventy bio Strikes Strategic Gene Therapy Deal with Novo Nordisk
2seventy bio (TSVT) has shared an announcement. 2seventy bio, Inc. has entered ...
06-27 04:48
2seventy bio’s Board Elections and Financial Oversight Update
The latest announcement is out from 2seventy bio (TSVT). At the 2024 Annual Mee...
06-12 05:04
Goldman cuts 2seventy bio to neutral, cites competition concerns
Goldman Sachs has downgraded 2seventy bio (NASDAQ:TSVT) to neutral, citing competition concerns. The investment bank said the biotech company faces a “challenging long-term outlook” due in part to com...
06-06 22:47
MiMedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Gainers: Processa Pharmaceuticals (PCSA) +45%. NewGenIvf Group (NIVF) +18%. Cidara Therapeutics (CDTX) +13%. Predictive Oncology (POAI) +10%. Zura Bio (ZURA) +6%. Losers: Cyclacel Pharmaceuticals (CYC...
04-25 22:00
